EXOZYMES INC. SEC Filings

eXoZymes Inc. is offering 35,555 units, each unit consisting of two shares of common stock and one warrant, representing 71,110 shares and 35,555 warrants sold together at $18.00 per unit. The warrants are exercisable from June 5, 2027 through June 5, 2031 at an initial exercise price of $11.24, subject to a one-time reset to $0.001 if the company issues later shares at a lower price prior to June 5, 2027 and certain holding conditions are met.

The placement agent is MDB Capital, an affiliate and substantial shareholder (holding 4,136,426 shares; 43.9% pre-offering). Net proceeds to the company are estimated at approximately $565,206. Shares outstanding prior to the offering are 9,210,249; as adjusted shares outstanding after this offering will be 9,281,359. The company discloses substantial going-concern risk and expects additional capital needs.

eXoZymes Inc. announced it has received a Notice of Award from the National Institute of General Medical Sciences of the NIH for a Phase IIB SBIR grant totaling $2,028,518. The two-year, non-dilutive grant is expected to begin on July 1, 2026 and supports development of rare cannabinoids and engineered cannabinoid analogs for pharmaceutical evaluation.

This award adds a second biosolution to eXoZymes’ pipeline after its NCT program and brings the company’s total non-dilutive funding to $19.7 million. Management highlights the grant as validation of its AI-enhanced, cell-free enzyme platform for scalable production of high-purity cannabinoids and new-to-nature molecules targeting future licensing and partnership opportunities.

eXoZymes Inc. completed an underwritten public offering of common stock and warrants, raising approximately $5.95 million in gross proceeds, including a partial exercise of the underwriters’ over-allotment option.

The company sold units combining common shares and warrants, with MDB Capital as sole book‑running manager, and plans to use the net proceeds to advance its N‑trans‑caffeoyltyramine (NCT) program, additional product opportunities, research and development, and general corporate and working capital needs.

eXoZymes Inc. is raising approximately $5.33 million through an underwritten public unit offering of common stock and warrants priced at $18.00 per unit. Each unit includes two shares and one warrant, with the offering made off an effective Form S-3 shelf registration.

The underwriter has a 45-day option to buy additional units, which could lift gross proceeds to $6.13 million before fees. Warrants become exercisable one year after the offering at $11.24 per share, can be redeemed once the stock trades at or above $17.98 for twenty out of thirty trading days, and include a reset feature that can cut the exercise price to $0.001 if eXoZymes sells stock or convertible securities below $8.99 within twelve months, subject to strict holding-period conditions for original investors.

Net proceeds, after underwriting commissions of about $0.37 million and estimated offering expenses of $0.25 million, are earmarked to advance the company’s N-trans-caffeoyltyramine (NCT) programs, other research and development, and general corporate and working capital needs.

eXoZymes Inc. is offering 592,270 shares of common stock and 296,135 warrants as units (two shares plus one warrant) pursuant to a prospectus supplement. Units are priced at $18.00 per unit; the offering includes a 45-day 15% over-allotment option. Each Warrant is exercisable beginning one year after the offering at $11.24 and expires five years after issuance, with a one-time exercise-price reset provision to $0.001 under specified conditions and a redemption feature at $0.01 per Warrant when the share price meets the stated trigger. Net proceeds are estimated at approximately $4,704,300 (or $5,447,891 if the over-allotment is exercised) to be used for developing the Company’s NCT program, next-in-line products, R&D, working capital and capital expenditures.

eXoZymes Inc. is conducting a proposed underwritten offering of units, each consisting of two shares of common stock and one warrant, under a preliminary prospectus supplement dated June 4, 2026. The filing states 8,478,992 shares outstanding and a public float value of $15,165,341 based on 8,478,992 shares and a per-share price of $11.70 as of April 10, 2026. MDB Capital Holdings is the largest pre-offering holder with 4,136,426 shares (representing 47.79%).

The units pair two common shares with one warrant exercisable beginning one year after issuance and expiring five years after issuance, subject to a potential exercise-price reset to $0.001 if the company issues equity at a lower price within one year. Warrants are redeemable for $0.01 under specified trading-price conditions. The offering includes a 45-day, up-to-15% overallotment option, a 7% underwriting discount, and underwriter warrants equal to 10% of shares and underlying securities sold.

eXoZymes Inc. is offering units consisting of two shares of common stock and one common-stock purchase warrant, together with separate Warrants exercisable for one share each. The prospectus supplement sets terms including a two-year warrant term, potential issuer call/redemption mechanics, and a 45-day 15% over-allotment option.

The filing discloses that MDB Capital Holdings beneficially holds 4,136,426 shares (47.79%) and that Lucid Capital Markets will act as the FINRA-qualified independent underwriter for a $175,000 fee. The company reports a public float of $15,165,341 based on 8,478,992 shares and a reference price of $11.70 as of April 10, 2026. Use of proceeds is stated for NCT program development, R&D, working capital and general corporate purposes.

eXoZymes Inc. reported another pre-revenue quarter for the three months ended March 31, 2026, with a net loss of $2.37 million, wider than the $1.86 million loss a year earlier. Higher research and development spending, which nearly doubled to $1.12 million, and increased compensation costs drove the larger loss.

Cash and cash equivalents fell to $1.44 million after operating cash outflows of $1.52 million, leaving working capital of about $0.51 million. Management states there is substantial doubt about the company’s ability to continue as a going concern without new funding and is pursuing grants and a proposed public equity offering of approximately $15 million under an existing $50 million shelf registration.

eXoZymes Inc. filed a current report to share an updated investor presentation dated May 7, 2026. The presentation is being provided to potential underwriters, other offering participants, and investors in connection with a proposed public offering of the company’s securities.

The report lists the presentation as Exhibit 99.1 and includes a cover page interactive data file as Exhibit 104. eXoZymes is a Nevada corporation whose common stock trades on the Nasdaq Capital Market under the symbol EXOZ.